Safety and Effectiveness of Lamivudine When Given Once a Day Versus Twice a Day in Combination With Other Anti-HIV Drugs in HIV-Infected Adults Who Have Never Received Anti-HIV Drugs

• Status: Completed
• Trial end date: 1969-12-31

Summary

The purpose of this study is to look at the safety and effectiveness of receiving lamivudine (3TC) once a day versus twice a day as part of an anti-HIV drug combination.

• Phase: Phase 2

Details

• Lead Sponsor: Glaxo Wellcome
• Treatments: Efavirenz; Lamivudine; Zidovudine